Arrhythmogenic actions of the Ca2+ channel agonist FPL-64716 in Langendorff-perfused murine hearts

Experimental Physiology

Volumn 94, Issue 2, 2009, Pages 240-254

  Ghais, Nina S ^a   Zhang, Yanmin ^a   Grace, Andrew A ^a   Huang, Christopher L H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL STIMULATING AGENT; CYCLOPIAZONIC ACID; DILTIAZEM; FPL 64716; NIFEDIPINE; UNCLASSIFIED DRUG; 4 (2 BENZYLBENZOYL) 2,5 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID METHYL ESTER; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CONTROLLED STUDY; ELECTROSTIMULATION; EXTRACELLULAR CALCIUM; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HYPOKALEMIA; ISOLATED HEART; LONG QT SYNDROME; MOUSE; NONHUMAN; REENTRY ARRHYTHMIA; ACTION POTENTIAL; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; HEART; HEART ARRHYTHMIA; HEART MUSCLE CELL; HOMEOSTASIS; METABOLISM; MOUSE STRAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; SARCOPLASMIC RETICULUM;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; DILTIAZEM; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; HEART; HOMEOSTASIS; INDOLES; MICE; MICE, INBRED STRAINS; MYOCYTES, CARDIAC; NIFEDIPINE; PYRROLES; SARCOPLASMIC RETICULUM; TACHYCARDIA, VENTRICULAR;

EID: 58649111966     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2008.044669     Document Type: Article

References (71)

1. Badaoui A, Huchet-Cadiou C & Leoty C (1995). Effects of cyclopiazonic acid on membrane currents, contraction and intracellular calcium transients in frog heart. J Mol Cell Cardiol 27, 2495 2505.
2. 2+ homeostasis. Am J Physiol Heart Circ Physiol 289, H1584 H1593.
3. Balasubramaniam R, Chawla S, Mackenzie L, Schwiening CJ, Grace AA & Huang CL-H (2004). Nifedipine and diltiazem suppress ventricular arrhythmogenesis and calcium release in mouse hearts. Pflugers Arch 449, 150 158.
4. Balasubramaniam R, Grace AA, Saumarez RC, Vandenberg JI & Huang CL-H (2003). Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1. J Physiol 552, 535 546.
5. 2+ content of rabbit ventricular muscle. Circ Res 73, 813 819.
6. Baxter AJ, Dixon J, Ince F, Manners CN & Teague SJ (1993). Discovery and synthesis of methyl 2,5-dimethyl-4-[2- (phenylmethyl)benzoyl]-1H-pyrrole-3- carboxylate (FPL 64176) and analogues: the first examples of a new class of calcium channel activator. J Med Chem 36, 2739 2744.
7. Bers DM (2002a). Calcium and cardiac rhythms: physiological and pathophysiological. Circ Res 90, 14 17.
8. Bers DM (2002b). Cardiac excitation-contraction coupling. Nature 415, 198 205.
9. Bers DM (2008). Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 70, 23 49.
10. Bethell HW, Vandenberg JI, Smith GA & Grace AA (1998). Changes in ventricular repolarization during acidosis and low-flow ischemia. Am J Physiol Heart Circ Physiol 275, H551 H561.
11. Bloomfield DM, Bigger JT, Steinman RC, Namerow PB, Parides MK, Curtis AB, Kaufman ES, Davidenko JM, Shinn TS & Fontaine JM (2006). Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol 47, 456 463.
12. 2+-ATPase in frog atrial fibres. Eur J Pharmacol 264, 69 76.
13. Cerrone M, Colombi B, Santoro M, di Barletta MR, Scelsi M, Villani L, Napolitano C & Priori SG (2005). Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res 96, 77 82.
14. Danik S, Cabo C, Chiello C, Kang S, Wit AL & Coromilas J (2002). Correlation of repolarization of ventricular monophasic action potential with ECG in the murine heart. Am J Physiol Heart Circ Physiol 283, H372 H381.
15. Fabritz L, Kirchhof P, Franz MR, Eckardt L, Monnig G, Milberg P, Breithardt G & Haverkamp W (2003). Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. Basic Res Cardiol 98, 25 32.
16. Fan JS & Palade P (2002). Effects of FPL 64176 on Ca transients in voltage-clamped rat ventricular myocytes. Br J Pharmacol 135, 1495 1504.
17. 2+ channels in cardiac myocytes. Naunyn Schmiedebergs Arch Pharmacol 361, 465 476.
18. Goddard CA, Ghais NS, Zhang Y, Williams AJ, Colledge WH, Grace AA & Huang CL-H (2008). Physiological consequences of the P2328S mutation in the ryanodine receptor (RyR2) gene in genetically modified murine hearts. Acta Physiol (Oxf) 194, 123 140.
19. 2+-transport ATPase in rat skeletal muscle sarcoplasmic reticulum vesicles. Biochem Pharmacol 37, 978 981.
20. Gussak I & Antzelevitch C (2000). Early repolarization syndrome: clinical characteristics and possible cellular and ionic mechanisms. J Electrocardiol 33, 299 309.
21. Harding SE, Jones SM, O'Gara P, del Monte F, Vescovo G & Poole-Wilson PA (1992). Isolated ventricular myocytes from failing and non-failing human heart; the relation of age and clinical status of patients to isoproterenol response. J Mol Cell Cardiol 24, 549 564.
22. Head CE, Balasubramaniam R, Thomas G, Goddard CA, Lei M, Colledge WH, Grace AA & Huang CLH (2005). Paced electrogram fractionation analysis of arrhythmogenic tendency in DeltaKPQ Scn5a mice. J Cardiovasc Electrophysiol 16, 1329 1340.
23. Hondeghem L (2007). Relative contributions of TRIaD and QT to proarrhythmia. J Cardiovasc Electrophysiol 18, 655 657.
24. 2+ channel agonist Bay K 8644. Circ Res 62, 563 571.
25. 2+ release (SOICR). Proc Natl Acad Sci U S A 101, 13062 13067.
26. 2+ release channel (ryanodine receptor) mutant associated with ventricular tachycardia and sudden death. Circ Res 91, 218 225.
27. Kass RS & Tsien RW (1982). Fluctuations in membrane current driven by intracellular calcium in cardiac Purkinje fibers. Biophys J 38, 259 269.
28. Killeen MJ, Gurung IS, Thomas G, Stokoe KS, Grace AA & Huang CL-H (2007a). Separation of early afterdepolarizations from arrhythmogenic substrate in the isolated perfused hypokalaemic murine heart through modifiers of calcium homeostasis. Acta Physiol (Oxf) 191, 43 58.
29. Killeen MJ, Thomas G, Olesen SP, Demnitz J, Stokoe KS, Grace AA & Huang CL-H (2007b). Effects of potassium channel openers in the isolated perfused hypokalaemic murine heart. Acta Physiol (Oxf) 193, 25 36.
30. 2+ channel activator, FPL 64176, in GH3 cells. Mol Pharmacol 42, 666 670.
31. Laurita KR & Katra RP (2005). Delayed after depolarization-mediated triggered activity associated with slow calcium sequestration near the endocardium. J Cardiovasc Electrophysiol 16, 418 424.
32. 2+ channels. Naunyn Schmiedebergs Arch Pharmacol 360, 122 128.
33. Lee HC, Mohabir R, Smith N, Franz MR & Clusin WT (1988). Effect of ischemia on calcium-dependent fluorescence transients in rabbit hearts containing indo-1. Correlation with monophasic action potentials and contraction. Circulation 78, 1047 1059.
34. Lee HC, Smith N, Mohabir R & Clusin WT (1987). Cytosolic calcium transients from the beating mammalian heart. Proc Natl Acad Sci USA 84, 7793 7797.
35. Marban E, Robinson SW & Wier WG (1986). Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle. J Clin Invest 78, 1185 1192.
36. Marks AR, Reiken S & Marx SO (2002). Progression of heart failure: is protein kinase A hyperphosphorylation of the ryanodine receptor a contributing factor? Circulation 105, 272 275.
37. Mason RP, Campbell SF, Wang SD & Herbette LG (1989). Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 36, 634 640.
38. V1.2 L-type calcium channels: dissociation of effects on ionic current and gating current. Biophys J 88, 211 223.
39. Milberg P, Hilker E, Ramtin S, Cakir Y, Stypmann J, Engelen MA, Mönnig G, Osada N, Breithardt G, Haverkamp W & Eckardt L (2007). Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol 18, 647 654.
40. Noble D, Sarai N, Noble PJ, Kobayashi T, Matsuoka S & Noma A (2007). Resistance of cardiac cells to NCX knockout. A model study. Ann NY Acad Sci 1099, 306 309.
41. 2+ in mammalian cardiac muscle. Nature 304, 735 738.
42. Papadatos GA, Wallerstein PMR, Head CEG, Ratcliff R, Brady PA, Benndorf K, Saumarez RC, Trezise AEO, Huang CL-H, Vandenberg JI, Colledge WH & Grace AA (2002). Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci USA 99, 6210 6215.
43. Pogwizd SM, Schlotthauer K, Li L, Yuan W & Bers DM (2001). Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual β-adrenergic responsiveness. Circ Res 88, 1159 1167.
44. ++ channel activators, BAY K 8644 and FPL 64176. J Pharmacol Exp Ther 265, 1125 1130.
45. 2+ channel activators, (S)-Bay K 8644 and FPL 64176, in smooth muscle. Mol Pharmacol 41, 599 602.
46. Rampe D & Lacerda AE (1991). A new site for the activation of cardiac calcium channels defined by the nondihydropyridine FPL 64176. J Pharmacol Exp Ther 259, 982 987.
47. Roden DM (2003). A surprising new arrhythmia mechanism in heart failure. Circ Res 93, 589 591.
48. Sabir IN, Li LM, Grace AA & Huang CL-H (2008a). Restitution analysis of alternans and its relationship to arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts. Pflugers Arch 455, 653 666.
49. Sabir IN, Li LM, Jones VJ, Goddard CA, Grace AA & Huang CL-H (2008b). Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome. Pflugers Arch 455, 637 651.
50. Saumarez RC, Chojnowska L, Derksen R, Pytkowski M, Sterlinski M, Huang CL-H, Sadoul N, Hauer RNW, Ruzyłło W & Grace AA (2003). Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation. Circulation 107, 2595 2600.
51. Saumarez RC & Grace AA (2000). Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases. Cardiovasc Res 47, 11 22.
52. Schwinger RH, Brixius K, Bavendiek U, Hoischen S, Müller-Ehmsen J, Bolck B & Erdmann E (1997). Effect of cyclopiazonic acid on the force-frequency relationship in human nonfailing myocardium. J Pharmacol Exp Ther 283, 286 292.
53. Scoote M & Williams AJ (2004). Myocardial calcium signalling and arrhythmia pathogenesis. Biochem Biophys Res Commun 322, 1286 1309.
54. 2+-ATPase of sarcoplasmic reticulum. J Biol Chem 264, 17816 17823.
55. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, Sanguinetti MC & Keating MT (2005). Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA 102, 8089 8096 discussion 8086-8088.
56. V1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119, 19 31.
57. 2+-dependent cellular mechanical oscillations. J Gen Physiol 82, 119 153.
58. Stokoe KS, Balasubramaniam R, Goddard CA, Colledge WH, Grace AA & Huang CLH (2007a). Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/- murine hearts modelling the Brugada syndrome. J Physiol 581, 255 275.
59. Stokoe KS, Thomas G, Goddard CA, Colledge WH, Grace AA & Huang CLH (2007b). Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Δ murine hearts modelling long QT syndrome 3. J Physiol 578, 69 84.
60. Takahashi S, Kato Y, Adachi M, Agata N, Tanaka H & Shigenobu K (1995). Effects of cyclopiazonic acid on rat myocardium: inhibition of calcium uptake into sarcoplasmic reticulum. J Pharmacol Exp Ther 272, 1095 1100.
61. 2+ channel antagonism on ventricular arrhythmogenesis in murine hearts containing a modification in the Scn5a gene modelling human long QT syndrome 3. J Physiol 578, 85 97.
62. Thomas G, Killeen MJ, Gurung IS, Hakim P, Balasubramaniam R, Goddard CA, Grace AA & Huang CL-H (2007b). Mechanisms of ventricular arrhythmogenesis in mice following targeted disruption of KCNE1 modelling long QT syndrome 5. J Physiol 578, 99 114.
63. v1 (L-type) calcium channels. Kluwer Academic/Plenum Publishing, New York.
64. Turner I, Huang CLH & Saumarez RC (2005). Numerical simulation of paced electrogram fractionation: relating clinical observations to changes in fibrosis and action potential duration. J Cardiovasc Electrophysiol 16, 151 161.
65. Wasserstrom JA, Wasserstrom LA, Lokuta AJ, Kelly JE, Reddy ST & Frank AJ (2002). Activation of cardiac ryanodine receptors by the calcium channel agonist FPL-64176. Am J Physiol Heart Circ Physiol 283, H331 H338.
66. Wehrens XH & Marks AR (2003). Altered function and regulation of cardiac ryanodine receptors in cardiac disease. Trends Biochem Sci 28, 671 678.
67. Wier WG, Kort AA, Stern MD, Lakatta EG & Marban E (1983). Cellular calcium fluctuations in mammalian heart: direct evidence from noise analysis of aequorin signals in Purkinje fibers. Proc Natl Acad Sci USA 80, 7367 7371.
68. 2+-release channel tunnel: structures and mechanisms involved in ion translocation in ryanodine receptor channels. Q Rev Biophys 34, 61 104.
69. 2+-ATPase, on the frequency-dependence of the contraction-relaxation cycle of the guinea-pig isolated atrium. Br J Pharmacol 113, 1001 1007.
70. Zaugg CE & Buser PT (2001). When calcium turns arrhythmogenic: intracellular calcium handling during the development of hypertrophy and heart failure. Croat Med J 42, 24 32.
71. 2+ channel activator, in cardiac and vascular preparations. Mol Pharmacol 40, 734 741.